Dimensional Fund Advisors LP recently announced the acquisition of new stake in Invesco Ltd (NYSE:IVZ). The institutional investor has increased its shareholding in the Financial company by 17.18% to 11.21 million shares with purchase of 1.64 million shares. This fresh investment now brings its stake to 2.49% valued currently at $199.92 million. In addition, Geode Capital Management LLC raised its holdings by 26222.0 to 9.63 million shares. And Northern Trust Investments, Inc. has lifted its position by 32.18% or 1.35 million shares – to 5.53 million shares.
Currently, there are 454.80M common shares owned by the public and among those 440.18M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 64 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 42 of these insider trades were purchases, accounting for 1,875,960 shares. Insider sales of the common stock occurred on 22 occasions, with total insider shares sold totaling 8,527,161 shares.
The top 3 mutual fund holders in Invesco Ltd are Vanguard Total Stock Market ETF, Vanguard Small Cap Index Fund, and Vanguard 500 Index Fund. Vanguard Total Stock Market ETF owns 13.77 million shares of the company’s stock, all valued at over $245.69 million. The company bought an additional 11379.0 shares recently to bring their total holdings to about 3.06% of the shares outstanding. Vanguard Small Cap Index Fund sold -0.17 million shares to see its total holdings shrink to 11.17 million shares valued at over $199.25 million and representing 2.48% of the shares outstanding. Vanguard 500 Index Fund bought 68437.0 shares to bring its total holdings to over 10.73 million shares at a value of $191.48 million. Vanguard 500 Index Fund now owns shares totaling to 2.39% of the shares outstanding.
However, the script later moved the day high at 17.52, up 1.76%. The company’s stock has a 5-day price change of 0.64% and 35.86% over the past three months. IVZ shares are trading -2.52% year to date (YTD), with the 12-month market performance down to -6.40% lower. It has a 12-month low price of $12.48 and touched a high of $20.56 over the same period. IVZ has an average intraday trading volume of 5.73 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -0.79%, 10.09%, and 11.08% respectively.
Institutional ownership of Invesco Ltd (NYSE: IVZ) shares accounts for 86.09% of the company’s 454.80M shares outstanding. Mutual fund holders own 38.27%, while other institutional holders and individual stakeholders account for 48.61% and 30.42% respectively.
It has a market capitalization of $7.82B and a beta (3y monthly) value of 1.46. The stock’s trailing 12-month PE ratio is 13.34, while the earnings-per-share (ttm) stands at $1.30. The company has a PEG of 1.94 and the debt-to-equity ratio at 0.56. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.33% over the week and 2.31% over the month.
Analysts forecast that Invesco Ltd (IVZ) will achieve an EPS of $0.4 for the current quarter, $0.4 for the next quarter and $1.74 for 2024. The lowest estimate earnings-per-share for the quarter is $0.37 while analysts give the company a high EPS estimate of $0.44. Comparatively, EPS for the current quarter was $0.39 a year ago. Earnings per share for the fiscal year are expected to decrease by -14.24%, and 21.40% over the next financial year. EPS should grow at an annualized rate of 6.89% over the next five years, compared to -11.55% over the past 5-year period.
Looking at the support for the IVZ, a number of firms have released research notes about the stock. TD Cowen stated their Outperform rating for the stock in a research note on January 04, 2024, with the firm’s price target at $21.
